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The resistance of Helicobacter pylori strains to clarithromycin is increasing in several developed
countries and their association with a genetic pattern circulation has been variously explained as
related to different geographical areas. In this study we have reported: the prevalence of the
resistance of H. pylori, isolated in Sicily, to clarithromycin; the principal point of mutation
associated with this resistance; and the more frequent association between resistance to
clarithromycin and cagA, the EPIYA motif, and the vacA and oipA genes. Resistance to
clarithromycin was detected in 25 % of cases, the main genetic mutation involved being
A2143G. The cagA gene was present in 48 % of cases and the distribution of the EPIYA motif
was: ABC in 35 cases; ABCC in 8 cases; ABCCC in 2 cases; ABC-ABCC in 2 cases; and
ABC-ABCC-ABCCC in 1 case. Regarding the vacA allele, an s1i1m1 combination was
detected in 35 % of cases, s1i1m2 in 12 %, s1i2m2 in 12 %, s2i2m2 in 40 %, and a double
s1m1-m2 mosaic in 1 % of cases. The status of the oipA gene was ‘off’ in 45 % of cases and
‘on’ in 55 %. Resistance to clarithromycin was found to be high in Sicily, but no correlation was
found among resistance to clarithromycin, the vacA gene and oipA status; a higher correlation
was observed between resistant strains and cagA-negative strains.
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INTRODUCTION
Helicobacter pylori infection is usually superficial and clini-
cally asymptomatic, but in approximately 10–20 % of cases
it can be more aggressive, being associated with other gas-
tric pathologies (Eusebi et al., 2014). Clarithromycin is the
key component used in eradication therapies (De Fran-
cesco et al., 2009). However, the prevalence of primary
resistance to clarithromycin is increasing in several devel-
oped countries (Megraud et al., 2013; De Francesco et al.,
2010a; Boyanova & Mitov, 2010). In Italy the overall pri-
mary resistance to clarithromycin can be detected in
35.2 % of cases, in France it can be detected in 26 % of
cases, while in Spain clarithromycin resistance is present
in 27.2 % of strains (Saracino et al., 2012; Agudo et al.,
2010; Raymond et al., 2010).
Clarithromycin acts by binding to the peptidyltransferase
region of 23S rRNA, thereby inhibiting protein synthesis
(Gerrits et al., 2006; Jones et al., 2008). The resistance to
clarithromycin in H. pylori has been shown to be due to
point mutations in the peptidyltransferase region of
domain V of the 23S rRNA. The most common mutation
is an A-to-G transition at position 2143 (A2143G), but
three point mutations – A2142G, A2144G and T2182C –
have also been described (Taylor et al., 1997; Alfaresi &
Elkoush, 2010). The presence of the A2143G point of
mutation has been shown to significantly affect the eradica-
tion rate of H. pylori. Consequently, investigating the distri-
bution of each mutated genotype for resistance to
clarithromycin is relevant for managing H. pylori in clinical
practice (Sakinc et al., 2012). Thus, various studies have
been performed in order to identify the relationship of the
mutated genotypes with the bacterial genetic factors involved
in virulence and clarithromycin sensitivity (Vannarath et al.,
2014; Agudo et al., 2010; Garcia et al., 2010).
The three main H. pylori genes correlated with pathogen-
icity are: cagA, vacA and oipA. The cagA, vacA and oipA
genotype markers are widely used to characterize
H. pylori virulence in relation to disease severity (Agudo
et al., 2010). The cagA pathogenicity island is a marker
of enhanced virulence, and it is associated with the
Abbreviations: CI, confidence interval; OR, odds ratio.
The GenBank/EMBL/DDBJ accession numbers for sequences of the
EPIYA ABC and EPIYA ABCC motifs are KM262820 and KM262821,
respectively.
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development of major gastroduodenal diseases, such as
peptic ulcers and gastric cancer (Hatakeyama & Higashi,
2005). VacA is capable of causing ‘vacuole’-like membrane
vesicles in the cytoplasm of gastric cells, but its role in
H. pylori pathogenesis remains unclear (Abadi & Lee,
2014). The oipA (outer inflammatory protein) gene
encodes one of the outer-membrane proteins involved in
the induction of IL-8 secretion by epithelial cells.
In patients living in Sicily it has been demonstrated that
high-virulence genotypes (i.e. cagA-positive and vacaA
s1m1) have been associated with the active form of chronic
gastritis, but no data are available with respect to clarithro-
mycin resistance and its correlation with the virulence
factors (Chiarini et al., 2009). According to the Maastricht
IV/Florence consensus report, the standard triple therapy
should be abandoned in areas with clarithromycin resist-
ance i20 % (i.e. Spain, Turkey, central Italy, Alaska,
China, Japan and Cameroon) (Malfertheiner et al., 2012).
On the basis of this evidence, the main aims of this study
were to assess and to expose high rates of resistance to clar-
ithromycin in Sicily in relation to the distribution of the
involved point mutations. Finally, we shall focus our inter-
est on verifying a possible association between resistance to
clarithromycin, point mutations and cagA, vacA and oipA
genes.
METHODS
Patients and sample collection. In this study a total of 100
H. pylori clinical strains were tested. These strains were obtained from
gastric biopsy samples of patients attending the endoscopy ward of
the Endoscopy Services of the Ospedali Civili Riuniti in Sciacca
(Agrigento, Italy), A.O.U.P. Paolo Giaccone (Palermo, Italy) and
M. Raimondi Hospital, San Cataldo (Caltanissetta, Italy). Exclusion
criteria for patient recruitment to the study were as follows: previous
attempts to eradicate H. pylori and use of antibiotics or proton pump
inhibitor within the 2 weeks prior to endoscopy. Each patient signed
an informed-consent form before endoscopy. The clinical strains were
isolated from adults whose mean age was 45 years (median 44 years,
ranging from 23 to 76 years), comprising 54 females and 46 males.
Antral and corpus biopsies taken from each patient were transferred
to the microbiology laboratory in cold transport medium (brain–
heart broth, Oxoid, supplemented with 15 % v/v glycerol and 10 % v/v
FCS). A further two gastric biopsy specimens from the antrum and
corpus were immersed in 10 % formalin and embedded in paraffin.
On the basis of endoscopic and histological findings, the diagnoses
were: inactive chronic gastritis in 39 cases, active chronic gastritis in
28 cases, duodenal peptic ulcer in nine cases, active chronic gastritis
with gastric or duodenal peptic ulcer in 13 cases, other diseases in 10
cases, and gastric cancer in only one case. Chronic inflammation was
defined on the basis of the increase in lymphocytes and plasma cells in
the lamina propria and activity when neutrophil infiltration of the
lamina propria, pits or surface epithelium were found. Regarding
microbiological analysis, biopsy samples were streaked onto Colom-
bia agar base (Oxoid) with 7 % horse blood and 0.4 % Dent sup-
plement (Oxoid). The plates were then incubated for 3–6 days at
37 uC in a microaerophilic atmosphere (7 % O2, 7.1 % CO2, 7.1 % H2
and 79.8 % N2), which was provided by CampyGen (Oxoid).
Identification of H. pylori. The isolates were presumptively ident-
ified as H. pylori on the basis of colony morphology and a positive
biochemical reaction to the following: cytochrome oxidase, catalase,
urease and a Gram stain.
DNA extraction. The genomic DNA of the 100 H. pylori strains was
extracted by using a High Pure Template Preparation kit (Roche), in
accordance with the manufacturer’s instructions. The DNA extracted
was stored at 220 uC until use.
Susceptibility test. With reference to the in vitro clarithromycin
susceptibility test of the H. pylori isolates, the inoculum was adjusted
in opacity until a 3–4 McFarland turbidity standard was reached.
It was then flooded onto Mueller–Hinton agar plates (Oxoid) con-
taining 7 % horse blood. The E-test strip, containing clarithromycin
(0.125–256 mg ml21; Abbiodisk), was placed onto the plate and then
dried, according to the manufacturer’s instructions. Incubation was
performed in a microaerophilic atmosphere for 48–72 h at 37 uC.
MIC was established according to the recommendations of the
European Committee on Antimicrobial Susceptibility Testing (http://
www.eucast.org/clinical_breakpoints/). The breakpoint used for
clarithromycin was w0.5 mg ml21.
We used disk diffusion susceptibility testing as a simple, cheap and
easy means to evaluate the susceptibility of H. pylori to drugs. The
E-test has been recommended because it has a more stable pattern of
antibiotic release and has been found to tolerate prolonged incu-
bation. Moreover, agar or broth dilution methods are difficult to
perform routinely.
Determination of point mutations in the H. pylori 23S rRNA
gene. In order to detect mutations related to clarithromycin resist-
ance in the 23S rRNA gene, PCR amplification methods and oligo-
nucleotide primers derived from a known sequence of the 23S rRNA
gene were used (sense, 59-ACG GCG GCC GTA ACT ATA-39, pos-
itions 2357 to 2375, GenBank accession number U27270; antisense,
59-TTA GCT AAC AGA AAC ATC AAG-39, positions 2635 to 2653,
GenBank accession number U27270) (Taylor et al., 1997; Kim et al.,
2008).
The PCR was carried out in a volume of 50 ml, according to the
method of Chiarini et al. (2009). The amplification was performed in
a Perkin-Elmer ThermoCycler 9700 under the following conditions:
95 uC for 10 min, followed by 40 cycles of 94 uC for 45 s, 50 uC
for 45 s and 72 uC for 45 s, and a final extension at 72 uC for 5 min.
The resulting PCR products were subjected to gel electrophoresis
in a 2 % agarose gel, subsequently purified and concentrated for
sequencing using Amicon Ultra 0.5 ml columns (Millipore). Purified
amplicons were sequenced directly with the same forward and
reverse primers as had already been used in the previous PCR, using
an ABI PRISM BigDye Cycle Sequencing Ready Reaction kit
(Applied Biosystems) according to the instructions supplied by the
manufacturer. The analysis of products was performed using BioEdit
v. 7.2.0 software.
Detection of cagA, the EPIYA motif, the typing of vacA alleles
and determining oipA status. In order to detect the presence of the
cagA gene and to analyse the EPIYA motif, the DNA from each strain
was subjected to PCR, as described by Panayotopoulou et al. (2007).
In determining the EPIYA motif, three different PCR products were
obtained: EPIYA ABC (550 bp), EPIYA ABCC (650 bp) (GenBank
accession numbers KM262820 and KM262821) and EPIYA ABCCC
(750 bp). The correct sequence of the EPIYA motif was confirmed in
all cases by sequencing, according to the procedure described in the
previous paragraph. The signal peptide (s) and mid-region (m) of the
vacA gene were amplified using the primers described by Atherton et al.
(1995). Four different PCR products were obtained: s1 (259 bp) and s2
(286 bp) from the s-region, andm1 (290 bp) andm2 (352 bp) from the
m-region (Atherton et al., 1995). Two different PCR products were
obtained from the i-region: i1 (250 bp) and i2 (260 bp) (Rhead et al.,
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2007). The oipA status was determined in all strains by PCR and the
sequencing of the signal region of the oipA gene, according to Yamaoka
et al. (2002).
Statistical methods. By means of univariate analysis, the association
between resistance to clarithromycin and demographic variables,
gastrointestinal symptoms, vacA, cagA, and oipA status was assessed
using the c2 test or Fisher’s exact test, as appropriate. In order to
measure the association level, crude odds ratios (ORs) were calculated
as the ratio between the odds of resistance to clarithromycin for
‘exposed’ and the odds of resistance to clarithromycin for ‘not
exposed’; corresponding 95 % confidence intervals (CIs) for ORs were
calculated on the natural log scale as exp{ln(OR)+SE[ln(OR)]}.
Fisher’s exact test was used to assess the statistical association between
gene combinations and EPIYA motif. A P-value j0.05 was con-
sidered statistically significant.
If more than one variable was significantly associated with resistance
to clarithromycin in the univariate analysis, they were included in a
multivariate logistic regression, in order to compute the adjusted ORs
and 95 % CI. The age variable was categorized with respect to the
median of the analysed sample. All analyses were performed using v.
11.0 StataMP software (StataCorp LP).
RESULTS
Clarithromycin resistance
The resistance to clarithromycin test demonstrated that 75
patients were infected with H. pylori-susceptible strains and
the remaining 25 with resistant strains. Nevertheless, a sig-
nificant difference regarding the resistance of H. pylori to
clarithromycin between female and male patients was high-
lighted. The analysis of the 23S rRNA gene also revealed a
strong association between the presence of point mutations
and macrolide resistance. The predominant point mutation
observed among the 25 H. pylori resistant strains was
A2143G in 20 cases (80 %) and A2142G in 5 cases
(20 %). However, the point mutations C2195T and
T2182C were detected in four cases (5 %) of H. pylori clar-
ithromycin-susceptible strains. No point mutation in the
23S rRNA gene was found in the remaining 71 (95 %) of
the clarithromycin-susceptible strains nor were any differ-
ences observed in the MIC values of the isolates with
A2143G or A2142G point mutation (data not shown).
The MICs of isolates are presented in Table 1.
cagA gene, EPIYA motif, vacA mosaicism
distribution and oipA status
The cagA gene and vacA (s- and m-regions) genotype were
assessed in all strains. The cagA gene was detected in 48 %
of cases. The EPIYA motif ABC was found in 35 (73 %) of
48 cagA-positive strains, ABCC in 8 (17 %) and ABCCC in
2 (4 %), and a mixed ABC-ABCC and ABC-ABCC-ABCCC
EPIYA motif was present in 2 (4 %) and 1 (2 %), respect-
ively, of the cagA-positive strains. In all cases the EPIYA
motif was confirmed by PCR product sequencing. Regard-
ing the vacA gene, the s1 allele was found in 60 cases, the
m1 allele in 37 cases and the i1 allele in 48 cases.
A double vacA mosaic combination was detected in only
one case (2 %). Specifically, the s1i1m1 combination was
observed in 35 cases, s1i1m2 in 12 cases, s1i2m2 in 12
cases, s2i2m2 in 40 cases and double mosaics s1i1-i2m1-
m2 were in 1 case. The distribution of vacA mosaicism
with respect to the cagA gene is shown in Table 2.
The absence of the cagA gene in six cases with the s1i1m1
combination of the vacA gene was confirmed using the
cag2 59-GGAACCCTAGTCGGTAATG-39 and cag4 59-ATC
TTTGAGCTTGTCTATCG-39 primers, according to Argent
et al. (2005).
There was found to be a strong association between the
presence of mosaic s1m1 and cagA positivity (29 cases
versus 6 cases, P-value v0.001) and between mosaic
s2m2 and cagA negativity (38 cases versus 2 cases,
P-value v0.001). The prevalence of the EPIYA pattern is
shown in Table 3. The oipA gene was detected in all strains,
thereby determining the oipA status by the number of CT
repeats. The ‘on’ status was observed in 55 strains while
the status was ‘off’ in the remaining 45. A total of 13 differ-
ent oipA sequencing patterns were detected. The most
prevalent in the ‘on’ frame status had six CT repeats, and
this was found to be the case in other studies (Matteo
et al., 2010). Among out-frame status ‘off’ variants, the
most prevalent were the patterns with eight CT repeats.
The strains being studied in this research showed more
Table 2. Distribution of vacA mosaicism between positive
and negative cagA strains
vacA mosaic cagA-positive
(48 cases)
cagA-negative
(52 cases)
P-value
s1i1m1 29 6 ,0.001
s1i1m2 10 2
s1i2m2 6 6
s2i2m2 2 38
s1m1-m2 1 0
Table 1. MIC of clarithromycin for 100 isolates of H. pylori by
E-test
MIC (mg ml21) No. H. pylori isolates
,0.125 58
0.125 9
0.19 6
0.38 2
4 2
6 6
8 8
12 4
16 1
32 3
48 1
T. Fasciana and others
1410 Journal of Medical Microbiology 64
Downloaded from www.microbiologyresearch.org by
IP:  147.163.71.65
On: Fri, 15 Apr 2016 17:04:10
than five CT repeats in the 59 region of oipA that were
specific for European strains (Kauser et al., 2005). The pre-
sence or absence of CTAA nucleotides may influence the
frame state of the gene. CT patterns and their distribution
are shown in Table 4. A close correlation was found
between the status of the oipA, vacA and cagA genes and,
indeed, the ‘on’ status occurred in 45 (89 %) of the
cagA-positive strains, being associated in 27 cases (35 %)
with s1m1 mosaicism.
The relationship of clarithromycin resistance with
vacA, cagA and oipA status
The cagA gene was variously distributed between suscep-
tible and resistant strains. Both cagA positivity and nega-
tivity were significantly associated with susceptibility
although the P-value was v0.001. In addition, when we
correlated cagA-positive to cagA-negative strains, a stron-
ger association with clarithromycin susceptibility in the
case of cagA-positive strains was observed. The number
of negative strains was higher in the context of resistant
strains than susceptible ones. Moreover, the association
between the cagA gene and resistance was not statistically
significant (Table 5).
Statistical analysis (Table 6) included crude ORs of resist-
ance to clarithromycin with respect to demographic vari-
ables, gastrointestinal symptoms, vacA, cagA and oipA
status. Only the gender variable was statistically significant
in the univariate analysis, and this was used to assess the
association between resistance or susceptibility to clarithro-
mycin and vacA, cagA or oipA status. With only one variable
significant in univariate analysis, multivariate analysis was
found not to be required.
DISCUSSION
Resistance to antimicrobials is mainly associated with wide
and indiscriminate use of antibiotics, and it can be con-
sidered a major cause of failure to eradicate H. pylori infec-
tions. Many reports have indicated that the prevalence of
resistance varies geographically and that there is a broad
range of resistance variability, depending on the use of
antimicrobials. Clarithromycin is recognized as the key
antibiotic for treating H. pylori, but, regrettably, the level
of primary resistance is increasing worldwide (De Fran-
cesco et al., 2010a,b).
An initial finding of this research is that the rate of H. pylori
resistance to clarithromycin is high, occurring in 25 % of
isolates throughout geographical areas in Sicily. It would
appear higher than computed in previous Italian studies,
but in agreement with the 23 % rate detected in the
study by De Francesco et al. (2006). Nevertheless, the
rate of H. pylori resistance to clarithromycin is lower
than that found in other countries, such as France and
Spain, and in recent Italian studies, which identified a
rate of between 26 and 35 % (Cellini et al., 2006; Saracino
et al., 2012). Of interest, H. pylori resistance to clarithromy-
cin has been found to be more frequently observed in
female than in male patients. A possible explanation for
this finding may be a wider use of antibiotics for curing
Table 3. Prevalence of the EPIYA pattern among 48 H. pylori
cagA-positive strains related to vacA genotype
EPIYA motif vacA mosaic
s1i1m1
(29)
s1i1m2
(10)
s1i2m2
(6)
s2i2m2
(2)
s1i1-i2m1-m2
(1)
ABC 21 5 6 2 1
ABCC 4 4 0 0 0
ABCCC 2 0 0 0 0
ABC-ABCC 1 1 0 0 0
ABC-ABCC-
ABCCC
1 0 0 0 0
P50.721.
Table 4. Frequency of the oipA CT repeat patterns according
to Yamaoka et al. (2002)
Sequence of signal peptide-encoding
region of oipA
No. of CT No. of
isolates
‘On’ status
ATGAAAAAAGCCCTCTTACTCTCT
CTCTCGTT
5 1
ATGAAAAAAGCCCTCTTGCTAACT
CTCTCTCTCTCGTTTTGGCT
6 31
ATGAAAAAAGCTCTTTTACTCTCT
CTCTCTCTCTCGTT
8 15
ATGAAAAAAGCTCTCTTACTAACT
CTCTCTCTCTCTCTCTCGTT
9 6
ATGAAAAAAGCTCTCTTACTCTCT
CTCTTTCTCTCGTT
5+2 2
Total 55
‘Off’ status
ATGAAAAAAGCTCTCTTACTAACT
CTCTCTCTCGTT
5 4
ATGAAAAAAGCCCTCTTACTCTCT
CTCTCTCGTT
6 4
ATGAAAAAAGCTCTCTTACTAACT
CTCTCTCTCTCTCGTT
7 6
ATGAAAAAAGCTCTCTTACTCTCT
CTCTCTCTCGTT
7 5
ATGAAAAAAACTCTCTTACTAACT
CTCTCTCTCTCTCTCGTT
8 15
ATGAAAAAAGCTCTCTTACTCTCT
CTCTCTCTCTCTCGTT
9 10
ATGAAAAAAGCTCTCTTACTAACT
CTCTCTCTCTCTCTCTCTCTCGTT
11 1
Total 45
Bold type indicates insertion of CTAA, italic bold type indicates inser-
tion of TT and underlining indicates the CT repeat.
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infections, with a greater prevalence in females, with, for
example, urinary tract infections (Giorgio et al., 2013).
Resistance to clarithromycin in H. pylori results from point
mutation in the peptidyltransferase loop region of the 23S
rRNA gene. In this study, the most frequent point
mutation (80 %) was A2143G. This mutation is predomi-
nant in H. pylori strains isolated not only from Europe
but also from Japan. The strong association between resist-
ance to macrolides and specific mutation in the 23S rRNA
gene was confirmed in all cases. Furthermore, only the
C2195T and T2182C mutations were not associated with
resistance to clarithromycin in strains described in this
paper (Agudo et al., 2010.), but we observed that these iso-
lates showed a higher MIC value equal to 0.38 mg ml21. The
cagA and vacA genes are widely used as markers to
characterize H. pylori virulence, and several epidemiologi-
cal studies have reported geographical variations in the cir-
culation of the virulence factors pertaining to micro-
organisms. In Sicily the cagA gene is present in 48 % of
strains, in 73 % of the strains it is associated with the
ABC EPIYA motif and in most it is associated with the pre-
sence of the s1m1 vacA allele.
The assessment of vacA gene mosaicism has revealed only
three out of the four possible combinations, s2m1 mosai-
cism never having been detected in the cases described in
this paper. This finding, in agreement with previous studies
(Atherton et al., 1995), probably depends on the selective
disadvantage of mosaicism, which undermines bacterial
viability. The equal distribution of s1m1 and s2m2 vacA
is in accordance with observations in other countries
[for example, in the US, where these are the most frequent
combinations (Atherton et al., 1995)]. However, and
according to a previous study (Han et al., 1998), s2m2
vacA mosaicism has been significantly associated with
cagA-negative status, and we observed that H. pylori infec-
tions were sustained by a single vacA mosaic. The preva-
lence of cagA found in the strains used in this research
was lower than that reported in Italy by De Francesco
et al., while the identified s1 and m1 vacA alleles were simi-
lar to those observed in that study (De Francesco et al.,
2006). No correlation was found between resistance to
macrolides and the ‘on’ status of the oipA gene.
Finally, this study has indicated that cagA-negative strains,
in addition to oipA ‘off’ status, seem more resistant to
clarithromycin than cagA-positive strains. The presence
of cagA-positive isolates, a more virulent genotype, may
damage the gastric epithelium extensively, and it is concei-
vable that, with inflamed mucosa, antibiotics can reach
higher concentrations. Another possible explanation for
resistance of H. pylori to clarithromycin is correlated with
the possibility that antibiotic activity interferes with the
metabolism of a dividing cell; cagA-positive strains may
proliferate faster than cagA-negative strains, and the latter
would, therefore, be more susceptible to antibiotics (van
Doorn et al., 2000).
In conclusion, the prevalence of H. pylori resistance to clar-
ithromycin is higher in Sicily and more frequently associ-
ated with s1m1, s1m2 vacA mosaicism and with cagA
negativity. We did not identify any relationship between
resistance to clarithromycin and the status of the oipA
gene. Using multivariate analysis, resistance to clarithro-
mycin was significantly associated with the female sex.
The results of this research indicate the advisability of
monitoring the status of resistance to clarithromycin in
Sicily because the efficacy of first-line therapy is expected
to decrease in the future. It would be particularly useful
to be able to test for resistance to clarithromycin prior to
commencing conventional triple therapy. An antimicrobial
susceptibility test is also recommended if the triple therapy
should be chosen in Sicily, where antibiotic resistance to
clarithromycin is high. Moreover, it is clear that the
Table 5. Association between cagA gene and clarithromycin
resistance
Clarithromycin
resistance
cagA-positive
(48 cases)
cagA-negative
(52 cases)
Resistant 9 16
Sensitive 39 36
OR, 0.52; 95 % CI, 0.18–1.44.
Table 6. Putative association of vacA, cagA and oipA with
resistance to clarithromycin: univariate analysis
Variable n Resistance to
clarithromycin
% Crude
ORa
95 %
CI
P
Gender 0.028
Male 47 7 14.9 1.00
Female 53 18 34.0 2.94 1.01; 9.25
Age (years) 0.247
j44 54 11 20.4 1.00
.44 46 14 30.4 1.71 0.62; 4.75
vacA 0.447
s1i1m1 35 12 34.3 1.00
s1i1m2 12 1 8.3 0.17 0.02; 1.67
s1i2m2 12 3 25.0 0.64 0.14; 2.87
s2i2m2 40 9 22.5 0.56 0.20; 1.57
s1m1-m2 1 0 0.0 – –
cagA 0.166
Negative 52 16 30.8 1.00
Positive 48 9 18.8 0.52 0.18; 1.44
oipA 0.202
On 55 11 20.0 1.00
Off 45 14 31.1 1.81 0.66; 5.02
Symptom* 0.080
GCNA 39 10 25.6 1.00
GCA 28 8 28.6 1.16 0.39; 3.48
PU 9 2 22.2 0.83 0.14; 4.75
Other diseases 10 4 40.0 1.93 0.44; 8.51
GCA+PU 13 0 0.0 – –
KG 1 1 100.00 – –
*GCNA, inactive chronic gastritis; GCA, active chronic gastritis; UP,
peptic ulcer; KG, gastric cancer.
aOdds ratio.
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inappropriate use of an anti-H. pylori regime will incur
heavy costs in terms not only of an initial ineffective treat-
ment but also of subsequent visits and investigations. Thus,
the clinical use of alternative medicines could also be envi-
saged in Sicily.
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